# The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT05673447** · EARLY_PHASE1 · UNKNOWN · sponsor: **Changhai Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD19 CAR NK cells

## Key facts

- **NCT ID:** NCT05673447
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673447, "The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05673447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*